Progression-free survival according to tissue or circulating tumor burden biomarkers. Kaplan-Meier estimates of PFS based on TMTV (A), CTC (B), cfDNA (C), and TMTV and cfDNA combined (D). Of the 21 patients with combined high or low levels, 17 had high cfDNA levels and a low TMTV, and 4 had low cfDNA levels and a high TMTV. H, high level; HR, hazard ratio; L, low level.